PMID: 7543216Aug 1, 1995Paper

Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins

Scandinavian Journal of Immunology
A AzumaM Shibuya

Abstract

Complement-dependent cytotoxicity (CDC) mediated by a chimeric anti-Lewis Y monoclonal antibody (cH18A; human IgG1) was investigated in this study. Human lung adenocarcinoma cell lines (PC7, PC9, and PC14) were used as the target cells. PC7 and PC9 cells, expressed Lewis Y antigen and were lysed by cH18A as effectively as by the parent mouse anti-Lewis Y antibodies (mH18A) in a concentration-dependent manner. PC14 cells did not express Lewis Y antigen and were not lysed by either cH18A or mH18A. cH18A mediated CDC activity against PC7 and PC9 cells was enhanced by the combined use of monoclonal antibodies directed against CD46(MCP), CD55(DAF), and CD59. These molecules are complement-regulatory proteins which protect host cells from CDC. PC7 and PC9 cells, showed high levels of surface expression of these proteins, PC7 cells were more susceptible to cH18A-mediated CDC than PC9 cells. Use of multiple blocking antibodies to the complement-regulatory proteins produced more enhancement of cH18A-mediated CDC than a single antibody. Moreover, expression of CD55 and CD59 by PC7 and PC9 cells was decreased after treatment with PI-PLC, resulting in increased susceptibility to cH18A-mediated CDC. Although the reason is unknown, PC7 cells...Continue Reading

References

Nov 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·D Solter, B B Knowles
Jun 1, 1992·The British Journal of Medical Psychology·A Roberts, J M Williams
Jan 2, 1992·International Journal of Cancer. Journal International Du Cancer·Y UraP P Major
Apr 1, 1988·The Journal of Clinical Investigation·N K CheungM E Medof
Mar 15, 1988·International Journal of Cancer. Journal International Du Cancer·K ZenitaR Kannagi
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N K CheungN A Berger
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Mar 1, 1993·The American Journal of Medicine·D M Goldenberg

❮ Previous
Next ❯

Citations

Nov 10, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·L ThorsteinssonP M Johnson
Jun 21, 2006·Biochimica Et Biophysica Acta·Jan-Henrik MikeschBurkhard Brandt
Nov 9, 2000·European Journal of Immunology·L SpendloveL G Durrant
Apr 1, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·V T BlokA Gorter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.